← Ascendis Pharma A/S (ASND) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Ascendis Pharma A/S (ASND)
Pharmaceutical Preparations · market cap $14.2B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
10
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
Ascendis Pharma A/S (ASND) is a Danish-American specialty pharmaceutical company with ~1,017 employees and a $14.95B market cap, built around its proprietary TransCon prodrug platform designed to extend the half-life of existing therapeutic proteins. Its most advanced asset is lonapegsomatropin (TransCon hGH), a once-weekly growth hormone replacement in Phase 3 for pediatric growth hormone deficiency, alongside a broader pipeline spanning achondroplasia, adult GHD, Turner syndrome, and oncology. The stock trades at ~$277, above the analyst consensus mean target of ~$292, with 18 analysts rated strong buy.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 2 · Navepegritideimp 7/10
- 2027-08-15 (est.)Phase 2 · Navepegritideimp 7/10
- 2027-08-15 (est.)Phase 2 · TransCon IL-2 β/γimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ACP-001 (TransCon hGH) | Phase 2 | Adult Growth Hormone Deficiency |
| TransCon hGH | Phase 3 | Growth Hormone Deficiency, Pediatric |
| ACP-001 | Phase 2 | Growth Hormone Deficiency (GHD) |
| Navepegritide | Phase 2 | Achondroplasia |
| TransCon CNP | Phase 3 | Achondroplasia |
| Somatropin | Phase 2 | Turner Syndrome |
| Once weekly subcutaneous injection of TransCon hGH | Phase 3 | Growth Hormone Deficiency, Pediatric |
| TransCon IL-2 β/γ | Phase 2 | Advanced Solid Tumor |
| Lonapegsomatropin | Phase 3 | Growth Hormone Deficiency |
| Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections | Phase 2 | Achondroplasia |
Price & technical context
3-month
-17.2%
6-month
-0.4%
12-month
+14.3%
52-wk range
$196.01–$277.18
vs 50-day MA
-8.8%
vs 200-day MA
-3.5%
Realized vol
38.8%
Max drawdown
-22.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ASND (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.